Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!

List view / Grid view

Screening

 

Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.

Sheraz Gul, Head of Drug Discovery at the Fraunhofer Institute for Molecular Biology and Applied Ecology – ScreeningPort
Sheraz Gul, Head of Drug Discovery at the Fraunhofer Institute for Molecular Biology and Applied Ecology – ScreeningPort
editorial-board

Sheraz Gul

6 February 2015 | By

Head of Drug Discovery at the Fraunhofer Institute for Molecular Biology and Applied Ecology

Screening In-Depth Focus 2014
Screening In-Depth Focus 2014
article

Screening In-Depth Focus 2014

7 May 2014 | By Kenji Schorpp, Christophe Antczak, Balajee Somalinga, Hakim Djaballah

In this Screening In-Depth Focus: Kenji Schorpp looks at targeting the ubiquitin-proteasome system, and experts from Memorial Sloan-Kettering Cancer Center discuss a high content assay opportunity to measure cellular stress response using heat shock proteins...

Pills
Pills
article

Building GPCR screening cascades for lead generation

6 May 2014 | By , , ,

Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…

Brian F. Volkman, Department of Biochemistry, Medical College of Wisconsin
Brian F. Volkman, Department of Biochemistry, Medical College of Wisconsin
article

Nuclear Magnetic Resonance as a tool for chemokine inhibitor discovery

1 May 2014 | By

Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…